Forte Biosciences, Inc. (FBRX)

US — Healthcare Sector
Peers: ZIVO  RNXT  TPST  IKNA  GYRE  VRPX  GRTX  BYSI  IPHA 

Automate Your Wheel Strategy on FBRX

With Tiblio's Option Bot, you can configure your own wheel strategy including FBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FBRX
  • Rev/Share 0.0032
  • Book/Share 8.3968
  • PB 1.7864
  • Debt/Equity 0.0
  • CurrentRatio 11.7357
  • ROIC -0.443

 

  • MktCap 186492810.0
  • FreeCF/Share -3.291
  • PFCF -4.8252
  • PE -4.1497
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.8538

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation FBRX Guggenheim -- Buy -- $75 Aug. 18, 2025
Initiation FBRX TD Cowen -- Buy -- -- Jan. 21, 2025

News

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
FBRX
Published: September 15, 2025 by: Business Wire
Sentiment: Neutral

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital” at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland).

Read More
image for news Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
FBRX
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be.

Read More
image for news Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

About Forte Biosciences, Inc. (FBRX)

  • IPO Date 2017-04-13
  • Website https://www.fortebiorx.com
  • Industry Biotechnology
  • CEO Paul A. Wagner
  • Employees 14

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.